Stay updated on Omalizumab in CRSwNP: Extension Study Clinical Trial
Sign up to get notified when there's something new on the Omalizumab in CRSwNP: Extension Study Clinical Trial page.

Latest updates to the Omalizumab in CRSwNP: Extension Study Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov page’s site revision label changed from v3.8.0 to v3.8.1.SummaryDifference0.0%

- Check9 days agoChange DetectedThe completed Phase 3 study record for Hoffmann-La Roche’s omalizumab extension trial is displayed, with details on eligibility, study design and outcomes, and 79 study locations.SummaryDifference92%

- Check16 days agoChange DetectedThe footer’s site revision changed from v3.7.2 to v3.8.0; the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check30 days agoChange DetectedAn NIH-wide notice about terminology changes appears above the existing 403 error page. The site revision label changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check44 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1 while the page continues to display a 403 error.SummaryDifference0.2%

- Check58 days agoChange DetectedThe study page is currently presenting a 403 Forbidden error page instead of the study details, with a simple Home link displayed on the error screen.SummaryDifference19%

Stay in the know with updates to Omalizumab in CRSwNP: Extension Study Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Omalizumab in CRSwNP: Extension Study Clinical Trial page.